Treatment
Pld clinical trials
We’re tracking 15 recruiting studies that include Pld, each written for real people, not researchers, below.
Recruiting studies
- NCT06014528RecruitingPhase 2
IN10018 plus liposomal doxorubicin for platinum-resistant ovarian cancer
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
BeijingAges 18 years+ - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT05536102RecruitingPhase 2
Surgery-plus chemo and immunotherapy for HER2-negative gastric cancer
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
ShanghaiAges 18–75 - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07604766RecruitingPhase 3
Rina-S for platinum-resistant ovarian cancer in China
This study tests a new cancer drug called Rina-S (an antibody-drug conjugate, which is a targeted therapy that delivers medicine directly to cancer cells) compared to standard treatment options for ovarian cancer that has returned or worsened after platinum chemotherapy. The trial is specifically for patients in China whose cancer is resistant to platinum drugs.
ChangchunAges 18 years+ - NCT06787612RecruitingPhase 2
New combination for platinum-resistant ovarian cancer
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
Birmingham, AlabamaAges 18 years+ - NCT05551507RecruitingPhase 1/Phase 2
Test drug IN10018 plus chemotherapy for platinum-resistant ovarian cancer
This trial tests IN10018 together with standard chemotherapy in people with high-grade serous ovarian (or related) cancer that has come back or progressed soon after platinum treatment. The goal is to see if adding IN10018 can improve cancer control and safety.
AnyangAges 18 years+ - NCT06981637RecruitingPhase 2
PLD vs. observation for advanced soft tissue sarcoma
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Kaohsiung CityAges 18 years+ - NCT07564141RecruitingPhase 3
New Drug for Recurrent Ovarian Cancer After Chemotherapy
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Danbury, ConnecticutAges 18 years+ - NCT07037446Enrolling by invitation
Occlutech leak device for mitral or aortic paravalvular leaks
This registry tracks the safety and effectiveness of a device designed to close leaks around heart valves (mitral or aortic). It may be an option for people who have significant symptoms like heart failure or anemia from these leaks and are not good candidates for surgery.
KatowiceAges 18 years+ - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT07286266RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Randwick, New South WalesAges 18 years+ - NCT05029999RecruitingPhase 1
Test drugs for HER2-negative advanced breast cancer
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
Chicago, IllinoisAges 18–99 - NCT05159193RecruitingPhase 3
Pre-surgery chemotherapy and antibodies for HER2 breast cancer
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Guandong, GuangdongAges 18–70
What Pld is being studied for
Conditions with recruiting Pld studies.
Common questions
- Are there clinical trials studying Pld?
- Yes. Clin2 currently lists 15 recruiting studies that include Pld, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pld trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pld an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pld or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.